首页> 外文期刊>American Journal of Pathology >Gene Expression of Osteoprotegerin Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Giant Cell Tumor of Bone : Possible Involvement in Tumor Cell-Induced Osteoclast-Like Cell Formation
【24h】

Gene Expression of Osteoprotegerin Ligand, Osteoprotegerin, and Receptor Activator of NF-{kappa}B in Giant Cell Tumor of Bone : Possible Involvement in Tumor Cell-Induced Osteoclast-Like Cell Formation

机译:骨巨细胞瘤中骨保护素配体,骨保护素和NF- {kappa} B受体激活剂的基因表达:可能与肿瘤细胞诱导的破骨细胞样细胞形成有关

获取原文
获取原文并翻译 | 示例
       

摘要

Giant cell tumor of bone (GCT) is a rare primary osteolytic tumor of bone that is characterized by massive tissue destruction at the epiphysis of long bones. There is no evidence that tumor cells themselves are capable of bone destruction; instead, it appears that the tumor cells of GCT act by promoting osteoclastogenesis and, as a consequence, osteoclastic bone resorption. However, the mechanism by which this is achieved is not understood. Here we attempted to determine whether osteoprotegerin ligand (OPGL), the factor that is necessary and essential for osteoclastogenesis, is involved in tumor cell-recruited osteoclast-like giant cell formation in GCT. Using fluorescence in situ hybridization, we sought to determine mRNA expression of OPGL, its receptor RANK, and its decoy receptor OPG in three major cell types of GCT. We demonstrated that OPG mRNA was expressed in all three cell types of GCT, OPGL transcripts were mainly detected in spindle-shaped stromal-like tumor cells, whereas RANK was expressed only in macrophage-like mononuclear cells and multinuclear osteoclast-like giant cells. By semiquantitative RT-PCR, we also showed that the level of OPGL mRNA in GCT is much higher than that in normal bone and osteogenic osteosarcoma. In contrast, a similar level of OPG transcripts was detected in these three kinds of tissues, and RANK mRNA was detectable only in GCT tissues. We have further examined the regulation of gene expression of OPGL and OPG in tumor cells in response to osteotropic hormones. Administration of 1,25(OH)2D3 and dexamethasone resulted in maximum up-regulation of OPGL level and down-regulation of OPG level in cultured GCT stromal-like tumor cells and the mouse bone marrow-derived ST-2 stromal cell line. Furthermore, we have shown that tumor cells of GCT induce differentiation of RANK-expressing myeloid RAW264.7 cells into osteoclast-like cells in the presence of 1,25(OH)2D3 and dexamethasone. Our findings suggest that OPGL is involved in the tumor cell-induced osteoclast-like cell formation in GCT. The ratio of OPGL/OPG by tumor cells may contribute to the degree of osteoclastogenesis and bone resorption.
机译:骨巨细胞瘤(GCT)是一种罕见的原发性骨溶解性骨肿瘤,其特征是长骨的骨massive发生大规模的组织破坏 。没有证据表明肿瘤 细胞本身能够破坏骨骼。取而代之的是, 似乎是GCT的肿瘤细胞通过促进破骨细胞生成而起作用,因此, 促进了破骨细胞的骨吸收。但是,实现该机制的 机制尚不清楚。在这里,我们尝试确定是否存在骨保护素配体(OPGL),破骨细胞形成所必需和必需的因子,与肿瘤细胞招募有关的因子。sup> GCT中的破骨细胞样巨细胞 形成。使用荧光原位杂交,我们试图确定 RANK和诱饵受体OPG的mRNA表达。 > GCT。我们证明OPG mRNA在三种GCT细胞中均有表达,OPGL转录物主要在 纺锤形基质样肿瘤细胞中检测到,而RANK表达在 > 仅在巨噬细胞样单核细胞和多核破骨细胞样 巨细胞中存在。通过半定量RT-PCR,我们还显示,GCT中 的OPGL mRNA的水平远高于正常 骨和成骨性骨肉瘤。相比之下,在这三种组织中检测到的OPG转录物水平相似,仅在GCT组织中可检测到RANK mRNA。我们进一步 检查了 肿瘤细胞对骨质激素的响应对OPGL和OPG基因表达的调控。 1,25(OH) 2 D 3 和地塞米松的给药 导致OPGL水平的最大上调 GCT 基质样肿瘤细胞和小鼠骨髓源性ST-2 基质细胞系中OPG的表达和下调。此外,我们已经显示,在存在GCT的情况下,GCT的肿瘤细胞 诱导表达RANK的骨髓RAW 264.7 细胞分化为破骨细胞样细胞。 1,25(OH) 2 D 3 和地塞米松。我们的研究结果表明,OPGL与 GCT中肿瘤细胞诱导的破骨细胞样细胞形成有关。肿瘤细胞中OPGL / OPG的比例可能有助于 破骨细胞生成和骨吸收的程度。

著录项

  • 来源
    《American Journal of Pathology》 |2000年第3期|761-767|共7页
  • 作者单位

    From the Department of Orthopaedic Surgery, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia;

    From the Department of Orthopaedic Surgery, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia;

    From the Department of Orthopaedic Surgery, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia;

    From the Department of Orthopaedic Surgery, University of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 14:17:17

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号